We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Trovagene Broadens Network of Commercial Distributors
News

Trovagene Broadens Network of Commercial Distributors

Trovagene Broadens Network of Commercial Distributors
News

Trovagene Broadens Network of Commercial Distributors

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Trovagene Broadens Network of Commercial Distributors"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Trovagene, Inc. has signed agreements with seven strategic partners across Europe and the Middle East for commercialization of the Trovera™ liquid biopsy tests.  This milestone marks the first wave of international distribution agreements for Trovagene's CLIA based liquid biopsy tests for urine and blood samples.


The initial partners will introduce Trovagene's liquid biopsy tests to physicians, laboratories and cancer centers in key regional markets.  In addition, these partners will have early access to Trovagene's research use only liquid biopsy kits and systems to distribute to clinical research facilities in Europe, Middle East, Africa and Asia.


These strategic partners include Alliance Global (AGBL) for the Middle East, Africa, Central and South Asia, Instituto Diagnostico Varelli (Italy), Progenetics (Israel), Amplitech (France, Belgium and Switzerland), NM Genomix (Bulgaria and East Europe), Diagnostica Longwood (Spain and Portugal), and Sorgente Genetica (Italy). 


"We are excited to announce that physicians and patients in these international markets now have access to our industry leading laboratory developed tests for EGFR, KRAS, and BRAF mutations in urine and blood," said Bill Welch, Chief Executive Officer of Trovagene.


Trovagene is pleased to partner with these premier life science and diagnostic organizations. In addition to the well-established clinical next-generation sequencing and research business channels they have created in their regions, this network also provides the infrastructure for scientific education, training and support of new technologies and future product introductions.


This article has been republished from materials provided by Trovagene. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement